Table 2.
Detailed results of subgroup analyses for clinicopathological features and prognostic significance
| Clinicopathological features | Number of studies | Number of patients | Total, OR (95% CI), P-value | Ethnicity, OR (95% CI), P-value
|
|
|---|---|---|---|---|---|
| Asian | European | ||||
| Age (<50 years vs ≥50 years) | 5 | 790 | 0.88 (0.65, 1.21), P=0.44 | 1.19 (0.73, 1.96), P=0.481 | 0.72 (0.48, 1.08), P=0.115 |
| Tumor diameter (<2 cm vs ≥2 cm) | 4 | 321 | 1.82 (0.51, 6.47), P=0.356 | 1.82 (0.51, 6.47), P=0.356 | – |
| Histological type (IDC vs others) | 6 | 888 | 1.23 (0.64, 2.37), P=0.535 | 1.21 (0.38, 3.89), P=0.743 | 1.21 (0.38, 3.06), P=0.681 |
| Histological grade (III vs I+II) | 6 | 620 | 1.56 (1.06, 2.29), P=0.023 | 1.78 (1.12, 2.85), P=0.016 | 1.2 (0.62, 2.32), P=0.59 |
| pTNM stage (III/IV vs I/II) | 5 | 416 | 1.45 (0.59, 3.55), P=0.414 | 1.45 (0.59, 3.55), P=0.414 | – |
| Lymph node metastasis (yes vs no) | 8 | 1,191 | 1.96 (1.01, 3.78), P=0.046 | 2.11 (1.00, 4.44), P=0.049 | 1.61 (0.25, 10.15), P=0.613 |
| Menopausal status (pre vs post) | 3 | 258 | 1.36 (0.80, 2.31), P=0.262 | 1.36 (0.80, 2.31), P=0.262 | – |
| OS | 8 | 736 | 1.55 (1.09, 2.22), P=0.015 | 2.22 (1.34, 3.68), P=0.002 | 1.09 (0.66, 1.81), P=0.725 |
| DFS | 3 | 490 | 1.06 (0.37, 3.07), P=0.909 | 0.72 (0.41, 1.25), P=0.241 | – |
Abbreviations: DFS, disease-free survival; IDC, invasive ductal carcinoma; OS, overall survival; –, no results due to insufficient studies.